The Clinical Research Of Qingfeiqutanfang On Treatment Of Acute Exacerbation Of Chronic Obstructive Pulmonary Disease Patients With Phlegm Heat Stagnation Syndrome And Its Effect On Inflammatory Markers

Objective:The aim of this study was to observe the clinical efficacy of QingFeiQuTanFang in treating AECOPD of Phlegm heat stagnation of lung syndrome and its effects on serum inflammatory markers CRP?IL-18 and SP-D,and preliminarily explore the mechanism of inhibiting airway inflammation.Methods:60 patients with phlegm-hest stagnating in the lung syndrome of AECOPD were randomly divided into treatment and control group,with 30 patients in each group.The control group was treated with routine western medicine,including the rational use of antibiotics,the regular use of anticholinergic drugs,phlegm and antiasthmatic drugs;The treatment group was treated with QingFeiQuTanFang on the basis of conventional western medicine.The course of treatment lasted for 10 days.Comparing the changes of Traditional Chinese Medicine(TCM)syndrome score,lung function,dyspnea and serum CRP?IL-18 and SP-D levels of the two groups before and after treatment.Results:1.After treatment,the total effective rate of the control group was 83.3%,and the total effective rate of the treatment group was 93.3%;The treatment group was better than the control group in improving the main symptoms of cough,phlegm,wheeze and chest tightness,but there was no difference in the improvement of fever and wheeze.2.After treatment,the FEV1%pred of the two groups were significantly higher than those before the treatment,and the improvement of the treatment group was better than the control group,The difference was statistically significant(P<0.01);however,both the treatment group and the control group did not significantly improve the patient's FEV1/FVC%,and there was no difference between the two groups(P>0.05).3.After treatment,the dyspnea of the two groups were obviously improved,and the improvement of dyspnea in the treatment group was better than that of the control group,and the difference was statistically significant(P<0.05).4.After treatment,the white blood cell count,neutrophil percentage and CRP level of the two groups were significantly decreased,and the decrease level of the treatment group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).5.After treatment,the levels of IL-18 and SP-D in the two groups were significantly decreased,and the decrease level in the treatment group was better than that in the control group,the difference was statistically significant(P<0.05).Conclusion:1.The combination of QingFeiQuTanFang with western medicine can improve the clinical symptoms and improve the total clinical efficiency of AECOPD patients.2.The combination of QingFeiQuTanFang with western medicine can improve the FEV1% level of lung function in AECOPD patients,and does not significantly improve FEV1/FVC% in short term,which can improve pulmonary ventilation function to some extent.3.The combination of QingFeiQuTanFang with western medicine can improve the score of dyspnea and improve the quality of life of the patients.4.The combination of QingFeiQuTanFang with western medicine can reduce peripheral blood leucocyte count,neutrophil percentage,CRP and IL-18 and SP-D levels in patients with AECOPD,suggesting that QingFeiQuTanFang may inhibit airway inflammation.